Janney Montgomery Scott LLC lessened its position in Novartis AG (NYSE:NVS) by 0.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 230,675 shares of the company’s stock after selling 1,519 shares during the period. Janney Montgomery Scott LLC’s holdings in Novartis were worth $19,718,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in NVS. Intersect Capital LLC grew its stake in Novartis by 4.1% in the 1st quarter. Intersect Capital LLC now owns 2,888 shares of the company’s stock valued at $247,000 after buying an additional 115 shares in the last quarter. Arkadios Wealth Advisors grew its stake in Novartis by 16.7% in the 1st quarter. Arkadios Wealth Advisors now owns 805 shares of the company’s stock valued at $68,000 after buying an additional 115 shares in the last quarter. Argent Advisors Inc. grew its stake in Novartis by 3.3% in the 4th quarter. Argent Advisors Inc. now owns 3,719 shares of the company’s stock valued at $351,000 after buying an additional 118 shares in the last quarter. Good Life Advisors LLC grew its stake in Novartis by 5.1% in the 1st quarter. Good Life Advisors LLC now owns 2,465 shares of the company’s stock valued at $210,000 after buying an additional 119 shares in the last quarter. Finally, STA Wealth Management LLC boosted its holdings in Novartis by 2.2% in the 4th quarter. STA Wealth Management LLC now owns 5,666 shares of the company’s stock valued at $535,000 after purchasing an additional 120 shares during the period. 9.86% of the stock is owned by institutional investors.
NYSE NVS opened at $86.39 on Tuesday. The stock has a 50-day moving average of $86.78 and a 200-day moving average of $88.54. The firm has a market cap of $197.72 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.49. Novartis AG has a 1-year low of $77.04 and a 1-year high of $98.52.
NVS has been the topic of a number of recent analyst reports. Sanford C. Bernstein assumed coverage on Novartis in a research report on Monday, March 22nd. They issued a “market perform” rating on the stock. UBS Group restated a “buy” rating on shares of Novartis in a research report on Monday, April 19th. Deutsche Bank Aktiengesellschaft began coverage on Novartis in a research note on Friday, January 15th. They set a “buy” rating for the company. Cowen lowered Novartis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $110.00 to $105.00 in a research note on Monday, February 1st. Finally, Oddo Bhf raised Novartis from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 28th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Novartis has a consensus rating of “Hold” and a consensus price target of $108.50.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
Featured Story: Stop Order
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.